Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer.

Abstract : Trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2; also known as HER-2/neu), is indicated for the treatment of women with either early stage or metastatic HER2(+) breast cancer. It kills tumor cells by several mechanisms, including antibody-dependent cellular cytotoxicity (ADCC). Strategies that enhance the activity of ADCC effectors, including NK cells, may improve the efficacy of trastuzumab. Here, we have shown that upon encountering trastuzumab-coated, HER2-overexpressing breast cancer cells, human NK cells become activated and express the costimulatory receptor CD137. CD137 activation, which was dependent on NK cell expression of the FcγRIII receptor, occurred both in vitro and in the peripheral blood of women with HER2-expressing breast cancer after trastuzumab treatment. Stimulation of trastuzumab-activated human NK cells with an agonistic mAb specific for CD137 killed breast cancer cells (including an intrinsically trastuzumab-resistant cell line) more efficiently both in vitro and in vivo in xenotransplant models of human breast cancer, including one using a human primary breast tumor. The enhanced cytotoxicity was restricted to antibody-coated tumor cells. This sequential antibody strategy, combining a tumor-targeting antibody with a second antibody that activates the host innate immune system, may improve the therapeutic effects of antibodies against breast cancer and other HER2-expressing tumors.
Type de document :
Article dans une revue
Journal of Clinical Investigation, American Society for Clinical Investigation, 2012, 122 (3), pp.1066-75. 〈10.1172/JCI61226〉
Liste complète des métadonnées

Littérature citée [54 références]  Voir  Masquer  Télécharger

http://www.hal.inserm.fr/inserm-00869052
Contributeur : Morgane Le Corre <>
Soumis le : mercredi 2 octobre 2013 - 14:20:09
Dernière modification le : lundi 26 mars 2018 - 15:38:11
Document(s) archivé(s) le : vendredi 3 janvier 2014 - 08:50:11

Fichier

JCI61226.pdf
Fichiers éditeurs autorisés sur une archive ouverte

Identifiants

Collections

Citation

Holbrook Kohrt, Roch Houot, Kipp Weiskopf, Matthew Goldstein, Ferenc Scheeren, et al.. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer.. Journal of Clinical Investigation, American Society for Clinical Investigation, 2012, 122 (3), pp.1066-75. 〈10.1172/JCI61226〉. 〈inserm-00869052〉

Partager

Métriques

Consultations de la notice

381

Téléchargements de fichiers

208